AMRI: Burlington 'money pit' is now a springboard
With the FDA's all-clear under its belt, AMRI's once-troubled Burlington, MA, "money pit" is poised to push the Albany, NY, company into new markets, the company's new CEO reportedly told investors at the J.P. Morgan Healthcare Conference last week. The former Teva executive said he's eyeing generics and high-tech drug delivery among potential expansion areas.
The start of 2014 has been a tumultuous period for Chinese manufacturers of hepatitis B vaccines, with three leading producers failing to gain quality certificates and authorities investigating 17 baby deaths. This week, China reassured its population there is no link between the vaccine and the deaths, but a history of cover-ups mean people are still suspicious.
While few question the necessity of the Defense Department's investments in protecting military personnel from biological threats, the scale and type of projects is a source of considerable controversy, as shown by the Pentagon's latest push into vaccine manufacturing.
After $2.6B deal, JLL targets more CMOs
Private equity outfit JLL Partners bet big on contract manufacturing last week with its $2.6 billion deal to combine Dutch Royal DSM with its portfolio CMO Patheon, and the fund's co-founder said the company's not done yet.
Pharmacyclics, J&J pick Catalent for blockbuster cancer drug
Pharmacyclics and Johnson & Johnson are riding high on an accelerated approval for the blockbuster hopeful Imbruvica, and now they've tapped Catalent to aid in commercial manufacturing and ongoing clinical trials for the cancer drug.
Capsugel bets $20M on Bend's commercial manufacturing
Deal-happy CMO Capsugel hasn't forgotten about its latest acquiree, planning to invest $20 million in Bend Research's spray-dried dispersion technology just a month after closing the buyout deal.
AMRI steers clear of FDA warning letter after years of fixes
With three year's of back-and-forth with the FDA under its belt, contract drug developer AMRI has finally closed the book on an agency warning letter tied to its Burlington, MA, plant, ending a protracted saga that has cost the company millions.
In August, a Wall Street analyst placed a headline-grabbing $0 price target on the stock of struggling cancer vaccine manufacturer Dendreon. Now, Dendreon has reportedly hired JP Morgan Chase to find someone who sees more value in the company and is willing to back their belief by acquiring the business.
Dendreon picks CMO PharmaCell to make Provenge in Europe
Dutch CMO PharmaCell has inked a deal with the struggling Dendreon to manufacture its prostate cancer drug Provenge in Europe.
Aenova snags Haupt to boost CMO presence
Germany's Aenova has sealed a deal for contract development and manufacturing outfit Haupt Pharma, a buyout that expands its capabilities and global reach.